Key Developments: C R Bard Inc (BCR)

BCR on New York Consolidated

167.35USD
28 Nov 2014
Price Change (% chg)

$0.18 (+0.11%)
Prev Close
$167.17
Open
$168.00
Day's High
$169.19
Day's Low
$167.19
Volume
223,675
Avg. Vol
516,698
52-wk High
$169.19
52-wk Low
$125.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

C R Bard Inc gives Q4 2014 guidance; EPS guidance in line with analysts' estimates; raises FY 2014 EPS guidance - Conference Call
Wednesday, 22 Oct 2014 05:00pm EDT 

C R Bard Inc:Expects Q4 2014 constant-currency sales growth between 8.5pct and 9.5pct.Expects Q4 2014 EPS of between $2.22 and $2.26.Raises FY 2014 EPS guidance of between $8.34 and $8.38.Q4 2014 revenue of $855 million and EPS of $2.26 - Thomson Reuters I/B/E/S.FY 2014 EPS of $8.31 - Thomson Reuters I/B/E/S.  Full Article

C R Bard Inc declares regular quarterly dividend
Wednesday, 8 Oct 2014 04:05pm EDT 

C R Bard Inc:Declares regular quarterly dividend of 22 cents per share on Bard's common stock.Dividend is payable on Oct. 31, to shareholders of record at the close of business on Oct. 20.  Full Article

C R Bard Inc gives Q3 2014 guidance; EPS guidance in line with analysts' estimates; raises FY 2014 EPS guidance; gives FY 2014 revenue guidance above analysts' estimates - Conference Call
Thursday, 24 Jul 2014 05:00pm EDT 

C R Bard Inc:Expects Q3 2014 constant currency sales growth between 7 pct and 9 pct.Expects Q3 2014 EPS in the range of $2.07 to $2.11 per share.Expects FY 2014 constant currency sales growth to be between 8 pct and 9 pct.Increases FY 2014 adjusted EPS guidance by $0.05 to $8.25 to $8.35 per share.Reported revenue of revenue of $3.049 billion in FY 2013.Q3 2014 revenue of $813 million and EPS of $2.10 - Thomson Reuters I/B/E/S.FY 2014 revenue of $3.275 billion and EPS of $8.28 - Thomson Reuters I/B/E/S.  Full Article

CR Bard Inc announces that circulatory system devices advisory panel provides unanimous favorable recommendation to FDA for lutonix drug coated balloon
Thursday, 12 Jun 2014 07:34pm EDT 

CR Bard Inc:Says that U.S. Food and Drug Administration's (FDA) circulatory system devices advisory panel provided unanimous favorable recommendation to FDA for use of Lutonix((reg))Drug Coated Balloon PTA Catheter (DCB) in U.S.Lutonix((reg))DCB is currently under review by FDA for improving luminal diameter and reducing incidence of restenosis for treatment of obstructive de novo or non-stented restenotic lesions (≤ 15 cm in length) in native femoropopliteal arteries with reference vessel diameters of 4 mm to 6 mm.If approved, it is expected that Lutonix((reg))DCB will be the first and only FDA-approved DCB available in the U.S.  Full Article

C R Bard Inc announces $500 mln share repurchase authorization
Wednesday, 11 Jun 2014 04:06pm EDT 

C R Bard Inc:Authorizes repurchase of up to $500 mln of the company's common stock.This is in addition to about $30 mln remaining under the prior authorization announced in Jan. 2014.  Full Article

C R Bard Inc increases quarterly dividend common
Wednesday, 11 Jun 2014 04:05pm EDT 

C R Bard Inc:Increases quarterly dividend common stock by 5 pct, to 22 cents per share.Payable on Aug. 1, of record on July 21.  Full Article

C R Bard Inc gives Q2 2014 guidance; EPS guidance in line with analysts' estimates; reaffirms FY 2014 EPS guidance - Conference Call
Tuesday, 22 Apr 2014 05:00pm EDT 

C R Bard Inc:Expects Q2 2014 constant currency sales growth between 6 pct and 8 pct.Expects Q2 2014 adjusted EPS in the range of $1.98 to $2.02 per share.Expects FY 2014 adjusted EPS of between $8.20 and $8.30.Q2 2014 revenue of $813 million and EPS of $2.02 - Thomson Reuters I/B/E/S.FY 2014 EPS of $8.20 - Thomson Reuters I/B/E/S.  Full Article

C R Bard declares quarterly dividend
Wednesday, 16 Apr 2014 04:05pm EDT 

C R Bard Inc:Declared a regular quarterly dividend of 21 cents per share.Payable on May 9 to shareholders of record on April 28.  Full Article

C R Bard Inc issues FY, Q1 2014 EPS guidance above analysts' estimates; comments on Q1 2014 revenue guidance - Conference call
Thursday, 30 Jan 2014 05:00pm EST 

C R Bard Inc:Expects FY 2014 adjusted cash EPS excluding any items affecting comparability of $8.20-$8.30.Expects Q1 2014 with adjusted cash EPS between $1.83 and $1.87 per share.Expect Q1 2014 sales growth to be between 6 pct. and 7 pct., including the first quarterly royalty payment being received from Gore.FY 2014 EPS of $7.51 - Thomson Reuters I/B/E/S.Q1 2014 EPS of $1.77 - Thomson Reuters I/B/E/S.Q1 2014 revenue of $795 mln - Thomson Reuters I/B/E/S.  Full Article

C R Bard Inc announces $500 mln share repurchase authorization
Thursday, 30 Jan 2014 04:06pm EST 

C R Bard Inc:Says its Board of Directors has authorized the repurchase of up to $500 mln of the company`s common stock.Says the new authorization is in addition to the about $55 mln remaining under the Company`s prior authorization.  Full Article

RPT-Boston Scientific faces first federal transvaginal mesh trials

Nov 3 - Boston Scientific Corp on Monday was set to face its first federal trials in two courts over claims from women who say they were injured by the company's transvaginal mesh devices.

Search Stocks